THU0209 4 years follow-up of a cohort of patients with rheumatoid arthritis in sustained clinical remission and optimisation of biological therapy

• Published in: Annals of the rheumatic diseases Vol. 77; no. Suppl 2; p. 324
• Main Authors: Ladehesa Pineda, M.L., Castro Villegas, M.C., Romero Gómez, M., Bautista Aguilar, L., López Medina, C., Pérez Sánchez, L., Gómez García, I., Carreto Font, P., Escudero Contreras, A., Collantes Estévez, E., Font Ugalde, P.
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.06.2018
• Subjects: Immunotherapy; Patients; Remission; Rheumatoid arthritis; Rheumatoid factor; Statistical analysis; Variance analysis
• ISSN: 0003-4967; 1468-2060
• DOI: 10.1136/annrheumdis-2018-eular.5719

BackgroundThe objectives of Rheumatoid Arthritis (RA) treatment comprise achieving persistent Clinical Remission (CR) or sustained low clinical activity. Nowadays management follows a “treat to target” strategy based on adjustment of treatment in accordance with protocolos. In patients with persistent disease activity after treatment with at least two of the classic disease-modifying antirheumatic drugs the use of biological therapy is recommended. Once sustained CR is achieved, the most efficient strategy is optimisation, by tapering the dose of the biological therapy or by increasing administration intervals. Searching for the lowest effective dose for each patient could minimise the risk of adverse effects and improve the cost-effectiveness of RA treatment.ObjectivesTo proof that the performance of an optimisation strategy in patients with RA and sustained CR under biological treatment maintains the proportion of patients with DAS28 ≤2,6 after 4 years, to assess the maintenance of the effectivenes of the optimisation at 4 years in terms of clinical manifestations, and to analyse the time until relapse.MethodsAn open observational prospective study that included 70 patients with RA (CREATE registry) in CR at least for 6 months, under treatment with tapered dose of biological therapy (TNFi, abatacept or tocilizumab). Treatment effectiveness was assessed with the main variable DAS28 ≤2,6. Statistical analysis included a descriptive study of variables and a confidence interval of 95% (95% CI) was estimated. For bivariate analysis, we used Student t-test for independent samples, repeated measures analysis of variance and mixed analysis of variance, and as a post-hoc contrast, Sidak adjustment. The log-rank test was used to compare the time until relapse according to the biological therapy.ResultsThe mean age of the patients was 56,9 (13,7) years, 78,6% were women, 68,8% were rheumatoid factor (RF) positive and 66,7% ACPA positive; the mean DAS28 at the beginning of the optimisation was 2,24 (0,73). After 4 years, 27,7% (95%CI:16,82%–38,58%) of patients maintained CR with the optimised dose, with a DAS28 2,15 (0,81). Through the first year, the percentage of relapses was 15,71%, in the second year, 7,35% and 4,61% relapsed during the third year. The median time of optimisation until relapse was 13,833,18 months (95% CI:7,6–20,06). No significative differences were found at comparing the survival curves of the optimised patients until relapse for 4 years according to the biological therapy (TNFi vs no TNFi) (log-rank test:0,865, p:0,352) (graphic).ConclusionsAfter 4 years, all of the patients maintained DAS28 levels of low disease activity, including those who had suffered a previous relapse and had turned back to the previous dose of biologic treatment. In view of this outcomes, optimisation strategy in clinical practice is posible and effective in patients with persistently controlled RA.Disclosure of InterestNone declared